EHA 2018 | MRD measurement as a strategy for treatment-free survival

Ola Landgren

Could patients who remain MRD negative long-term whilst on maintenance treatment cease treatment? Here, Ola Landgren, MD, PhD, from Memorial Sloan Kettering Cancer Center, NY, discusses the utilization of MRD measurement as a strategy for treatment-free survival. This video was recorded at the 23rd congress of European Hematology Association (EHA) 2018, held in Stockholm, Sweden.

Share this video